Home/Filings/4/0001144204-14-014206
4//SEC Filing

Baker Bros. Advisors (GP) LLC 4

Accession 0001144204-14-014206

CIK 0001070494other

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 5:27 PM ET

Size

21.4 KB

Accession

0001144204-14-014206

Insider Transaction Report

Form 4
Period: 2014-03-05
Transactions
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+11,738$334,533452,540 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+38,934$1,109,6191,552,055 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+475,644$13,555,85418,476,847 total(indirect: See Footnotes)
BAKER FELIX
10% Owner
Transactions
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+475,644$13,555,85418,476,847 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+38,934$1,109,6191,552,055 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+11,738$334,533452,540 total(indirect: See Footnotes)
BAKER JULIAN
10% Owner
Transactions
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+11,738$334,533452,540 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+38,934$1,109,6191,552,055 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+475,644$13,555,85418,476,847 total(indirect: See Footnotes)
667, L.P.
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+38,934$1,109,6191,552,055 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+475,644$13,555,85418,476,847 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+11,738$334,533452,540 total(indirect: See Footnotes)
14159, L.P.
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+475,644$13,555,85418,476,847 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+11,738$334,533452,540 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+38,934$1,109,6191,552,055 total(indirect: See Footnotes)
Transactions
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+38,934$1,109,6191,552,055 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+475,644$13,555,85418,476,847 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+11,738$334,533452,540 total(indirect: See Footnotes)
Transactions
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+38,934$1,109,6191,552,055 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+475,644$13,555,85418,476,847 total(indirect: See Footnotes)
  • Purchase

    Common Stock

    2014-03-05$28.50/sh+11,738$334,533452,540 total(indirect: See Footnotes)
Footnotes (6)
  • [F1]On March 5, 2014, 667, L.P.("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667 and Life Sciences, the "Funds") purchased 38,934, 475,644 and 11,738 shares of the Issuer's Common Stock, respectively, pursuant to an underwritten public offering.
  • [F2]After giving effect to the transaction reported herein, and as a result of his ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • [F3]After giving effect to the transaction reported herein, and as a result of his ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  • [F4]After giving effect to the transaction reported herein, and as a result of his ownership interest in 14159 Capital (GP), LLC, Julian C. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Column 5 of Table I directly held by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.
  • [F5]The aggregate indirect beneficial ownership reported on this form is 20,481,442 shares.
  • [F6]Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Issuer

ACADIA PHARMACEUTICALS INC

CIK 0001070494

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001580575

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 5:27 PM ET
Size
21.4 KB